Journal of Developing Drugs
Open Access
ISSN: 2329-6631
ISSN: 2329-6631
Hong-yu Li
Associate Professor, Department of Pharmacology and Toxicology
The University of Arizona, USA
Hong-yu Li is currently an associate professor of Medicinal Chemistry in College of Pharmacy, the University of Arizona. He received his Ph.D. degree from the University of Tokyo, and did his postdoctoral trainings at Columbia University (with Professor Koji Nakanishi) and Harvard University (with Professor Yoshito Kishi). He previously worked at Eli Lilly where he focused on oncology drug discovery.His current research interests are in chemical biology and drug discovery, especially for oncology related targets and phenotypes.In his lab at the University of Arizona, a highly potent (picomolar activity in an oncogene-driven cancer cell line), selective, and orally bioavailable small molecule drug inhibitor was discovered, and is currently ready for preclinical development and further IND filing.
Hong-yu Li is currently an associate professor of Medicinal Chemistry in College of Pharmacy, the University of Arizona. He received his Ph.D. degree from the University of Tokyo, and did his postdoctoral trainings at Columbia University (with Professor Koji Nakanishi) and Harvard University (with Professor Yoshito Kishi). He previously worked at Eli Lilly where he focused on oncology drug discovery.His current research interests are in chemical biology and drug discovery, especially for oncology related targets and phenotypes.In his lab at the University of Arizona, a highly potent (picomolar activity in an oncogene-driven cancer cell line), selective, and orally bioavailable small molecule drug inhibitor was discovered, and is currently ready for preclinical development and further IND filing.